[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653269":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":36,"studyPopulation":29,"armGroups":37,"interventions":49,"overallOfficials":29,"centralContacts":57,"locations":63,"responsibleParty":78,"collaborators":29,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":29,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":29,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":29,"overallStatus":100,"whyStopped":29,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Huons Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":29},[9,13],{"measure":10,"description":11,"timeFrame":12},"AUCtau,ss","Area Under the Curve","Day 15",{"measure":14,"description":15,"timeFrame":12},"Cmax,ss","Maximum concentration at steady state",[17,20,23,26],{"measure":18,"description":19,"timeFrame":12},"Tmax,ss","Time to maximum concentration at steady state",{"measure":21,"description":22,"timeFrame":12},"t1\u002F2","Half-life",{"measure":24,"description":25,"timeFrame":12},"CLss\u002FF","Apparent Clearance",{"measure":27,"description":28,"timeFrame":12},"Vdss\u002FF","Apparent Volume of Distribution at Steady State",null,{"allocation":31,"interventionModel":32,"interventionModelDescription":29,"primaryPurpose":33,"observationalModel":29,"timePerspective":29,"maskingInfo":34},"RANDOMIZED","SEQUENTIAL","BASIC_SCIENCE",{"masking":35,"maskingDescription":29,"whoMasked":29},"NONE","This randomized, open-label, 2-arm, 2-period, multiple-dose, phase 1 clinical trial evaluates the safety, tolerability, and pharmacokinetics of HUC2A-752 following repeated oral administration of HUC2A-752-A and HUC2A-752-B in healthy adult volunteers.",[38,44],{"label":39,"type":40,"description":41,"interventionNames":42},"Losartan","EXPERIMENTAL","HUC2A-752-A",[43],"Drug: Losartan (COZZAR®)",{"label":45,"type":40,"description":46,"interventionNames":47},"Pitavastatin\u002FEzetimibe","HUC2A-752-B",[48],"Drug: Pitavastatin plus Ezetemibe",[50,54],{"type":51,"name":52,"description":41,"armGroupLabels":53,"otherNames":29},"DRUG","Losartan (COZZAR®)",[39],{"type":51,"name":55,"description":46,"armGroupLabels":56,"otherNames":29},"Pitavastatin plus Ezetemibe",[45],[58],{"name":59,"role":60,"phone":61,"phoneExt":29,"email":62},"Huons","CONTACT","+82-70-7492-6023","jywon@huons.com",[64],{"facility":65,"status":29,"city":66,"state":67,"zip":68,"country":69,"countryCode":29,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Seoul National University Hospital","Seoul","Jongno-gu","03080","South Korea",{"type":71,"coordinates":72},"Point",[73,74],126.9784,37.566,{"lat":74,"lon":73},[77],{"name":65,"role":60,"phone":61,"phoneExt":29,"email":62},{"type":79,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100653269","phase-1-a-phase-1-clinical-trial-to-evaluate-the-safety-and-the-pharmacokinetic-drug-drug-interaction-between-huc2a-752-a-and-huc2a-752-b-in-healthy-adults-100653269",false,"NCT07784621","A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults","An Open-Label, Multiple-oral Dosing, Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults","Inclusion Criteria:\n\n* Healthy adult volunteers\n* Individuals with a body weight between 50.0 kg and 90.0 kg and a BMI between 18.5 kg\u002Fm² and 29.9 kg\u002Fm²\n\nExclusion Criteria:\n\n* Individuals with a history or presence of clinically significant diseases of the following systems: hepatobiliary, renal, neurological, immunological, respiratory, gastrointestinal, endocrine, hematologic\u002Foncologic, cardiovascular , musculoskeletal, urological, psychiatric, or sexual dysfunction.\n* Individuals with a history of gastrointestinal diseases or gastrointestinal surgeries that could affect the safety or pharmacokinetic evaluation of the investigational product.\n* Individuals with a history of hypersensitivity or clinically significant hypersensitivity reactions to losartan, pitavastatin, ezetimibe, angiotensin receptor blockers, statins, or any other medications.",true,"ALL","19 Years","64 Years",{"count":92,"type":93},30,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","This study evaluates the pharmacokinetic drug-drug interactions of repeated co-administration of HUC2A-752-A and HUC2A-752-B compared to monotherapy of each agent in healthy adults",[99],"Hypertension","NOT_YET_RECRUITING","2026-09-06",{"date":103,"type":104},"2026-09-10","ACTUAL",{"date":106,"type":93},"2026-10",{"date":108,"type":93},"2027-02",{"name":5,"class":6},1]